TR201310724A2 - Linagliptinin farmasotik formulasyonları. - Google Patents

Linagliptinin farmasotik formulasyonları. Download PDF

Info

Publication number
TR201310724A2
TR201310724A2 TR2013/10724A TR201310724A TR201310724A2 TR 201310724 A2 TR201310724 A2 TR 201310724A2 TR 2013/10724 A TR2013/10724 A TR 2013/10724A TR 201310724 A TR201310724 A TR 201310724A TR 201310724 A2 TR201310724 A2 TR 201310724A2
Authority
TR
Turkey
Prior art keywords
linagliptin
pharmaceutical
formulati
ons
pharmaceutically acceptable
Prior art date
Application number
TR2013/10724A
Other languages
English (en)
Inventor
Hasan Turp Ali̇
Saydam Mehtap
Türkyilmaz Ali̇
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2013/10724A priority Critical patent/TR201310724A2/tr
Priority to EP14184491.0A priority patent/EP2848242A1/en
Priority to EP22151084.5A priority patent/EP4019003A1/en
Priority to EP14184471.2A priority patent/EP2848241A1/en
Priority to ES14184462T priority patent/ES2936832T3/es
Priority to EP14184462.1A priority patent/EP2853257B1/en
Publication of TR201310724A2 publication Critical patent/TR201310724A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical formulation for therapeutically effective amount of linagliptin or pharmaceutically acceptable salt thereof comprising croscarmellose sodium and at least one other pharmaceutically acceptable excipient.
TR2013/10724A 2013-09-12 2013-09-12 Linagliptinin farmasotik formulasyonları. TR201310724A2 (tr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
TR2013/10724A TR201310724A2 (tr) 2013-09-12 2013-09-12 Linagliptinin farmasotik formulasyonları.
EP14184491.0A EP2848242A1 (en) 2013-09-12 2014-09-11 Orally disintegrating formulations of Linagliptin
EP22151084.5A EP4019003A1 (en) 2013-09-12 2014-09-11 Pharmaceutical formulations of linagliptin
EP14184471.2A EP2848241A1 (en) 2013-09-12 2014-09-11 Effervescent formulations of linagliptin
ES14184462T ES2936832T3 (es) 2013-09-12 2014-09-11 Formulaciones farmacéuticas de linagliptina
EP14184462.1A EP2853257B1 (en) 2013-09-12 2014-09-11 Pharmaceutical formulations of linagliptin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2013/10724A TR201310724A2 (tr) 2013-09-12 2013-09-12 Linagliptinin farmasotik formulasyonları.

Publications (1)

Publication Number Publication Date
TR201310724A2 true TR201310724A2 (tr) 2015-03-23

Family

ID=50030433

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2013/10724A TR201310724A2 (tr) 2013-09-12 2013-09-12 Linagliptinin farmasotik formulasyonları.

Country Status (3)

Country Link
EP (2) EP4019003A1 (tr)
ES (1) ES2936832T3 (tr)
TR (1) TR201310724A2 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156048A1 (en) * 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
CN107174571B (zh) * 2016-03-09 2021-01-08 四川科伦药物研究院有限公司 一种利格列汀及其盐、酯、衍生物的药物组合物及其制备方法
EP3781135A4 (en) 2018-04-17 2021-12-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions comprising sitagliptin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
KR20130069615A (ko) * 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 피오글리타존 및 리나글립틴을 포함하는 약제학적 제형
US20140248345A1 (en) * 2011-10-24 2014-09-04 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin

Also Published As

Publication number Publication date
EP2853257B1 (en) 2022-11-02
EP2853257A1 (en) 2015-04-01
EP4019003A1 (en) 2022-06-29
ES2936832T3 (es) 2023-03-22

Similar Documents

Publication Publication Date Title
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12016500024A1 (en) Bromodomain inhibitor
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201792591A1 (ru) Фармацевтические препараты
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
DK3010891T3 (da) Amorf letermovir og faste farmaceutiske formuleringer deraf til oral indgivelse
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
EA201692298A1 (ru) Производные карбоксамидов
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
EA201890944A1 (ru) Фармацевтические композиции нилотиниба гидрохлорида
EA201691231A1 (ru) Фармацевтические лекарственные формы
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.